Monica Ferrer Socorro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Monica Ferrer Socorro has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Darius Ebrahimi-Fakhari
Movement Disorders Program, Department of Neurology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
3 shared publications - Kathryn Yang
Movement Disorders Program, Department of Neurology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
3 shared publications - Amy Tam
Movement Disorders Program, Department of Neurology & F.M. Kirby Neurobiology Center Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publications - Enrique Gonzalez Saez‐Diez
Movement Disorders Program, Department of Neurology & F.M. Kirby Neurobiology Center Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publications Zainab Zaman
Movement Disorders Program, Department of Neurology & F.M. Kirby Neurobiology Center Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publications- Adeline Vanderver
Department of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, United States
1 shared publication
Latest Publications
- 25 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (10) , 2737-2744
KIF1A ‐Associated Neurological Disorder ( KAND ): Spectrum of Movement and Motor Disorders in a Cohort of 51 Patients
Background: KIF1A ‐associated neurological disorder (KAND) encompasses a broad neurodevelopmental and neurodegenerative spectrum in which motor and movement disorders are common but incompletely defined. Objectives: To systematically characterize motor and movement disorder phenotypes in KAND. Methods: In this cross‐sectional study, 51 individuals with likely‐pathogenic or pathogenic KIF1A variants underwent standardized neurological assessment using the Spastic Paraplegia Rating Scale (SPRS), SPATAX disability scale, Gross Motor Function Classification System (GMFCS), and Modified Ashworth Scale. Results: A history of global developmental delay was present in 96.1% and neonatal or infantile hypotonia in 62.7%. Progressive spasticity occurred in 72.5%, predominantly affecting the lower extremities and correlated with age ( β = 0.45, odds ratio [OR] = 1.56, 95% confidence intervals [95% CI] 1.09–2.25, P = 0.016). Lower extremity weakness was nearly universal (88.2%) and inversely related with age ( β = −0.08, OR = 0.93, 95% CI 0.86–0.99, P = 0.032). Independent walking was achieved by 62.7% at a median age of 24 months, but only 31.4% retained independent ambulation at last evaluation. Movement disorders included motor stereotypies (43.1%), ataxia (19.6%), action tremor (15.6%), and dystonia (3.9%). Cerebellar signs were present in 37.2%. The p.Glu253Lys variant was associated with the most severe phenotype. Conclusions: KAND encompasses a continuous spectrum of motor and movement disorders that integrates developmental and neurodegenerative features. These findings inform clinical management, genetic counseling, and the design of future clinical trials. © 2026 International Parkinson and Movement Disorder Society.
- 25 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (10) , 2737-2744
KIF1A ‐Associated Neurological Disorder ( KAND ): Spectrum of Movement and Motor Disorders in a Cohort of 51 Patients
Background: KIF1A ‐associated neurological disorder (KAND) encompasses a broad neurodevelopmental and neurodegenerative spectrum in which motor and movement disorders are common but incompletely defined. Objectives: To systematically characterize motor and movement disorder phenotypes in KAND. Methods: In this cross‐sectional study, 51 individuals with likely‐pathogenic or pathogenic KIF1A variants underwent standardized neurological assessment using the Spastic Paraplegia Rating Scale (SPRS), SPATAX disability scale, Gross Motor Function Classification System (GMFCS), and Modified Ashworth Scale. Results: A history of global developmental delay was present in 96.1% and neonatal or infantile hypotonia in 62.7%. Progressive spasticity occurred in 72.5%, predominantly affecting the lower extremities and correlated with age ( β = 0.45, odds ratio [OR] = 1.56, 95% confidence intervals [95% CI] 1.09–2.25, P = 0.016). Lower extremity weakness was nearly universal (88.2%) and inversely related with age ( β = −0.08, OR = 0.93, 95% CI 0.86–0.99, P = 0.032). Independent walking was achieved by 62.7% at a median age of 24 months, but only 31.4% retained independent ambulation at last evaluation. Movement disorders included motor stereotypies (43.1%), ataxia (19.6%), action tremor (15.6%), and dystonia (3.9%). Cerebellar signs were present in 37.2%. The p.Glu253Lys variant was associated with the most severe phenotype. Conclusions: KAND encompasses a continuous spectrum of motor and movement disorders that integrates developmental and neurodegenerative features. These findings inform clinical management, genetic counseling, and the design of future clinical trials. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
- 25 April 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (8) , 1702-1710
Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation
This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7. GMFCS levels ranged from I to V. Following immunomodulation, interferon signatures normalized in 6/7 of patients, and 6/7 showed clinical stabilization or improvement, with no further regression events. These findings indicate that targeted therapy was associated with reduced systemic inflammation and stabilized disease. However, motor outcomes varied, suggesting that established CNS injury may limit functional recovery despite a biochemical response.
- 25 April 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (8) , 1702-1710
Open AccessMovement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation
This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7. GMFCS levels ranged from I to V. Following immunomodulation, interferon signatures normalized in 6/7 of patients, and 6/7 showed clinical stabilization or improvement, with no further regression events. These findings indicate that targeted therapy was associated with reduced systemic inflammation and stabilized disease. However, motor outcomes varied, suggesting that established CNS injury may limit functional recovery despite a biochemical response.
Delayed diagnosis in adolescent onset focal epilepsy: Impact on morbidity and mental health
Objective: This study was undertaken to investigate diagnostic delay in adolescent onset focal epilepsy, including reasons for longer delays and associated morbidities.Methods: Secondary analysis was done using enrollment data from the Human Epilepsy Project, a multi‐institutional cohort including 34 sites in the USA, Canada, Finland, Austria, and Australia (2012–2017). Participants were aged 11–64 years at enrollment and within 4 months of treatment initiation for newly diagnosed focal epilepsy. Participants with seizure onset at age ≤ 21 years were evaluated. Data included seizure diaries documenting onset, frequency, and characteristics of seizures, reasons for diagnostic delays, and prediagnosis morbidities, including injuries, suicidal ideation, and self‐injurious behaviors.Results: Of 152 participants with adolescent onset seizures, those with a diagnosis delay > 1 year experienced a median delay to diagnosis of 4.4 years and reported higher rates of initial nonmotor seizures compared to those diagnosed within 1 year (n = 55, 78.6% vs. n = 33, 40.2%; χ21 = 22.76, p < .001). Lack of recognition by patients and health care providers accounted for diagnostic delay in more than half (68.2%) of participants with initial nonmotor seizures. Notably, 70% of participants with initial nonmotor seizures went undiagnosed until development of motor seizures. This group reported more injuries compared to those who did not develop motor seizures (56.5% vs. 7.7%; χ22 = 19.82, p < .001). Those with time to diagnosis > 1 year had more prediagnostic seizures (67 vs. 5.5 seizures, 95% confidence interval = 16.0–94.0; p < .001) and higher rates of suicidal ideation (33.3% vs. 14.9%; χ21 = 6.27, p = .01), suicidal behaviors (13.8% vs. 1.5%; χ21 = 7.19, p = .007), and nonsuicidal self‐injurious behaviors (13.4% vs. 1.5%; χ21 = 7.04, p = .008).Significance: This study highlights significant delays in diagnosing adolescent onset focal epilepsy, especially in cases with nonmotor seizures. These delays, often due to lack of recognition by patients and health care providers, are linked to more frequent seizures, higher injury rates, and increased suicidal ideation and self‐injury. Early recognition and diagnosis may mitigate adverse outcomes and improve quality of life for adolescents with epilepsy.
Delayed diagnosis in adolescent onset focal epilepsy: Impact on morbidity and mental health
Objective: This study was undertaken to investigate diagnostic delay in adolescent onset focal epilepsy, including reasons for longer delays and associated morbidities.Methods: Secondary analysis was done using enrollment data from the Human Epilepsy Project, a multi‐institutional cohort including 34 sites in the USA, Canada, Finland, Austria, and Australia (2012–2017). Participants were aged 11–64 years at enrollment and within 4 months of treatment initiation for newly diagnosed focal epilepsy. Participants with seizure onset at age ≤ 21 years were evaluated. Data included seizure diaries documenting onset, frequency, and characteristics of seizures, reasons for diagnostic delays, and prediagnosis morbidities, including injuries, suicidal ideation, and self‐injurious behaviors.Results: Of 152 participants with adolescent onset seizures, those with a diagnosis delay > 1 year experienced a median delay to diagnosis of 4.4 years and reported higher rates of initial nonmotor seizures compared to those diagnosed within 1 year (n = 55, 78.6% vs. n = 33, 40.2%; χ21 = 22.76, p < .001). Lack of recognition by patients and health care providers accounted for diagnostic delay in more than half (68.2%) of participants with initial nonmotor seizures. Notably, 70% of participants with initial nonmotor seizures went undiagnosed until development of motor seizures. This group reported more injuries compared to those who did not develop motor seizures (56.5% vs. 7.7%; χ22 = 19.82, p < .001). Those with time to diagnosis > 1 year had more prediagnostic seizures (67 vs. 5.5 seizures, 95% confidence interval = 16.0–94.0; p < .001) and higher rates of suicidal ideation (33.3% vs. 14.9%; χ21 = 6.27, p = .01), suicidal behaviors (13.8% vs. 1.5%; χ21 = 7.19, p = .007), and nonsuicidal self‐injurious behaviors (13.4% vs. 1.5%; χ21 = 7.04, p = .008).Significance: This study highlights significant delays in diagnosing adolescent onset focal epilepsy, especially in cases with nonmotor seizures. These delays, often due to lack of recognition by patients and health care providers, are linked to more frequent seizures, higher injury rates, and increased suicidal ideation and self‐injury. Early recognition and diagnosis may mitigate adverse outcomes and improve quality of life for adolescents with epilepsy.